Home
About
Overview
Sharing Data
ORCID
Help
History (14)
Mometasone Furoate
Tungsten Compounds
Nasal allergen challenge generates 1-0-hexadecyl-2-lyso-sn-glycero-3-phosphocholine.
No universal mathematical model for thermal performance curves across traits and taxonomic groups.
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
See All 14 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer Res. 2012 May 15; 18(10):2809-16.
View in:
PubMed
subject areas
Antineoplastic Agents
Clinical Trials, Phase II as Topic
Humans
Medical Oncology
Neoplasms
Pharmacogenetics
Randomized Controlled Trials as Topic
authors with profiles
Peter O'Donnell